HIND 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-12

• The Company is a Cambridge, MA/Princeton, NJ/New Delhi, India-based clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions, with a business advantage of the US-India innovation corridor. The lead…

• On May 8, 2026, the Company entered into an in-licensing agreement with Impetis Biosciences Limited (a TATA Enterprise) relating to certain preclinical JAK inhibitor assets, pursuant to which the Company has no upfront payment obligations, development funding commitments, or milestone payment obliga…

• The Company derives revenues from the sale of products, including royalties related to sales of such products, and from the license of our technology. Substantially all revenues for the three months ended June 30, 2026, and 2025 were derived from one customer, Sun Pharma, based in India. We have a d…

• Revenues for the three months ended June 30, 2026 and 2025 are summarized as follows:

• Research and development expenses were $506,723 and $80,061 for the three months ended June 30, 2026 and 2025, respectively. The increase in research and development costs was primarily due to the focusing of the Company’s resources on scaling up the regulatory consulting and CMC preparation work of…

相对上期删除的文字 · 来源:10-Q · 2026-05-12

• The Company is a Cambridge, MA/Princeton, NJ/ New Delhi, India-based clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions, with a business advantage of the US-India innovation corridor. The lea…

• Comparison of the three months ended March 31, 2026 and 2025

• On March 27, 2026, the Company received an order from the GST authorities in India relating to the refund of Integrated Goods and Services Tax (IGST) of approximately ₹3.57 crore (~$400K) previously claimed on certain R&D services provided to its U.S. affiliate. The matter pertains to the determinat…

• The Company received a civil court notice with respect to deferred unpaid salary of approximately $95,000 to a past employee. Thies liability is already accrued in the balance sheet.

• We believe that our existing cash, together with the proceeds from the private placement offering, and proceeds from our ATM facility to date, will enable us to fund our operating expenses and capital expenditure requirements for at least 15 months, including the initiation of the pivotal trial of o…

相对上期删除的文字 · 来源:10-Q · 2026-05-12

• On May 8, 2026, the Company entered into an Exclusive License Agreement (the “Impetis License Agreement”), dated May 8, 2026, with Impetis Biosciences Limited (A TATA Enterprise, or “Impetis”), pursuant to which the Company was granted an exclusive license to manufacture, commercialize and distribut…

• The foregoing description of the Impetis License Agreement is qualified in its entirety by reference to the full text of the Impetis License Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein in its entirety by reference.